A Phase 2 Study of Reparixin in People with Myelofibrosis

Full Title

Purpose

Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body’s normal blood cell production. 

Reparixin may help treat myelofibrosis by blocking inflammatory signals of interleukin-8 (IL-8) by inhibiting the receptors CXCR1 and CXCR2. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have primary myelofibrosis, post-polycythemia myelofibrosis, or post-essential thrombocythemia myelofibrosis that cannot be treated with standard therapies.
• Have recovered from the serious side effects of prior treatments before taking reparixin.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Brian Chernak’s office at 646-608-4366.